Document is current
Any future updates will be listed below
-
Authors
Strunz, Patrick-Pascal https://orcid.org/0000-0002-3168-7074
Le Maire, Maxime https://orcid.org/0009-0000-1202-8447
Heusinger, Tobias https://orcid.org/0009-0002-8883-3404
Klein, Juliana https://orcid.org/0009-0009-4941-2683
Labinsky, Hannah https://orcid.org/0000-0001-5762-9182
Fleischer, Anna https://orcid.org/0009-0009-8760-3931
Luetkens, Karsten Sebastian https://orcid.org/0000-0001-7536-9409
Possler, Patricia https://orcid.org/0009-0007-1773-4763
Gernert, Michael https://orcid.org/0000-0003-0074-4459
Leppich, Robert https://orcid.org/0000-0003-4711-7743
Schmieder, Astrid https://orcid.org/0000-0002-6421-9699
Hammel, Ludwig https://orcid.org/0009-0003-8403-0652
Schulz, Evelin https://orcid.org/0009-0002-8116-4308
Sperlich, Billy https://orcid.org/0000-0003-4686-8561
Froehlich, Matthias https://orcid.org/0000-0001-7745-3903
Schmalzing, Marc https://orcid.org/0000-0002-3289-2299
-
Funding
Funding for this research was provided by:
Universitätsklinikum Würzburg
- License Information
-
More Information
Article History
Received: 23 March 2024
Accepted: 15 April 2024
First Online: 29 April 2024
Declarations
:
: Patrick-Pascal Strunz received speaker’s fees and travel grants from Janssen-Cilag Galapagos, Eli Lilly, Boehringer/Ingelheim and AbbVie (less than $10,000 each) as well as research funding from Chugai (25000$). Maxime Le Maire reported to be Chief Executive Officer of Applimeda, Co-Founder and shareholder of Applimeda GmbH. Tobias Heusinger reported to be Chief Regulatory & Medical Officer of Applimeda, Co-Founder and shareholder of Applimeda GmbH. Juliana Klein stated to be PRRC of Applimeda. Hannah Labinsky received travel grants from UCB, Boehringer Ingelheim, Pfizer, and Abbvie as well as compensations for consulting activity from Pfizer and for lecturing activities from Janssen. Anna Fleischer declared no conflict of interest. Karsten Sebastian Luetkens declared no conflict of interest. Patricia Possler declared no conflict of interest. Michael Gernertreceived travel grants, compensation for advisory boards or speaker’s fees from AbbVie, Chugai, Eli Lilly, Hexal, Janssen, Novartis, Pfizer, Takeda. Robert Leppich declared to be Chief Technology Officer of Applimeda, Co-Founder and shareholder of Applimeda GmbH. Astrid Schmieder declared no conflict of interest. Ludwig Hammel declared to be Former Chief Executive Officer of DVMB. Evelin Schulz declared to be Chief Executive Officer of DVMB. Billy Sperlich declared no conflict of interest. Matthias Froehlich received speaker’s fees, travel grants or compensation for board memberships from AbbVie, Novartis, Janssen, and Eli Lilly. Marc Schmalzing received speaker’s fees, travel grants, research funding, or compensation for consultancies or board memberships from AbbVie, Actelion, AstraZeneca, BMS, Boehringer/Ingelheim, Celgene, Chugai/Roche, Eli Lilly, Genzyme, Gilead, Hexal/Sandoz, Janssen-Cilag, MSD, Novartis, Pfizer, Sanofi Pasteur, Takeda (Shire), UCB (less than $ 10,000 each).
: This study was performed in line with the principles of the Declaration of Helsinki. The study was submitted to the ethics committee of the Medical Faculty of the University of Wuerzburg (DE/EKBY13) (Date December 4th, 2023, No 2023112302). The ethics committee considered the study to be part of the quality management process. Therefore, the study required no further ethical approval according to the national regularities.
: All participants provided informed consent to take part in the user tests and the survey. Furthermore, the participants gave informed consent for publication of the data.
